JP2021524439A5 - - Google Patents

Info

Publication number
JP2021524439A5
JP2021524439A5 JP2020564427A JP2020564427A JP2021524439A5 JP 2021524439 A5 JP2021524439 A5 JP 2021524439A5 JP 2020564427 A JP2020564427 A JP 2020564427A JP 2020564427 A JP2020564427 A JP 2020564427A JP 2021524439 A5 JP2021524439 A5 JP 2021524439A5
Authority
JP
Japan
Prior art keywords
alkyl
groups
substituted
hydrogen
formula
Prior art date
Application number
JP2020564427A
Other languages
English (en)
Japanese (ja)
Other versions
JP7508375B2 (ja
JP2021524439A (ja
JPWO2019222269A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/032292 external-priority patent/WO2019222269A1/en
Publication of JP2021524439A publication Critical patent/JP2021524439A/ja
Publication of JPWO2019222269A5 publication Critical patent/JPWO2019222269A5/ja
Publication of JP2021524439A5 publication Critical patent/JP2021524439A5/ja
Priority to JP2024098452A priority Critical patent/JP2024125338A/ja
Application granted granted Critical
Publication of JP7508375B2 publication Critical patent/JP7508375B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020564427A 2018-05-14 2019-05-14 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド Active JP7508375B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024098452A JP2024125338A (ja) 2018-05-14 2024-06-19 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671047P 2018-05-14 2018-05-14
US62/671,047 2018-05-14
PCT/US2019/032292 WO2019222269A1 (en) 2018-05-14 2019-05-14 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024098452A Division JP2024125338A (ja) 2018-05-14 2024-06-19 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Publications (4)

Publication Number Publication Date
JP2021524439A JP2021524439A (ja) 2021-09-13
JPWO2019222269A5 JPWO2019222269A5 (https=) 2022-05-20
JP2021524439A5 true JP2021524439A5 (https=) 2022-05-20
JP7508375B2 JP7508375B2 (ja) 2024-07-01

Family

ID=67002352

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564427A Active JP7508375B2 (ja) 2018-05-14 2019-05-14 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド
JP2024098452A Pending JP2024125338A (ja) 2018-05-14 2024-06-19 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024098452A Pending JP2024125338A (ja) 2018-05-14 2024-06-19 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Country Status (18)

Country Link
US (2) US11827664B2 (https=)
EP (1) EP3794009A1 (https=)
JP (2) JP7508375B2 (https=)
KR (1) KR20210021457A (https=)
CN (2) CN119285591A (https=)
AU (2) AU2019271126B2 (https=)
BR (1) BR112020023277A2 (https=)
CA (1) CA3100333A1 (https=)
CL (1) CL2020002957A1 (https=)
CO (1) CO2020015380A2 (https=)
EA (1) EA202092727A1 (https=)
IL (2) IL278698B2 (https=)
MX (2) MX2020012366A (https=)
PE (1) PE20211917A1 (https=)
PH (1) PH12020551941A1 (https=)
SG (1) SG11202011311YA (https=)
UA (1) UA130486C2 (https=)
WO (1) WO2019222269A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900660T1 (it) 2012-02-09 2020-01-14 Univ Kansas Inibitori c-terminali di hsp90
EP3793565B1 (en) 2018-05-14 2022-01-05 Gilead Sciences, Inc. Mcl-1 inhibitors
JP7508375B2 (ja) 2018-05-14 2024-07-01 リアタ ファーマシューティカルズ インコーポレイテッド 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CN114787139B (zh) 2019-11-26 2025-03-11 吉利德科学公司 用于制备mcl1抑制剂的方法和中间体
EP4247783A1 (en) 2020-11-19 2023-09-27 Gilead Sciences, Inc. Processes and intermediates for preparing macrocyclic mcl1 inhibitors
WO2023039293A1 (en) * 2021-09-13 2023-03-16 Rubedo Life Sciences, Inc. Coumarin derivatives of sugar analogs and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2091171A1 (en) 1990-09-07 1992-03-08 Adriano Afonso Antiviral compounds
DE19512886A1 (de) 1995-04-06 1996-10-10 Bayer Ag Substituierte Cycloalkene
FR2792320B1 (fr) 1999-04-19 2003-05-09 Hoechst Marion Roussel Inc Nouveaux amides aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments
AU2002223127A1 (en) 2000-11-30 2002-06-11 Kissei Pharmaceutical Co., Ltd. Intellectual Property Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
CA2456281A1 (en) 2001-09-21 2003-04-03 Novartis Ag Pyrane derivatives as both ace- and nep- inhibitors
US7208630B2 (en) 2004-10-27 2007-04-24 University Of Kansas Heat shock protein 90 inhibitors
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
WO2006050501A2 (en) 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
CA2620566A1 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008061108A2 (en) 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Phthalazine derivatives
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
JP5401329B2 (ja) 2007-03-20 2014-01-29 キュリス，インコーポレイテッド Ｈｓｐ９０インヒビターとしての縮合アミノピリジン
US7960353B2 (en) 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
ES2475206T3 (es) 2008-02-01 2014-07-10 Takeda Pharmaceutical Company Limited Derivados de oxima como inhibidores de HSP90
FR2928645A1 (fr) 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
US20100022635A1 (en) 2008-07-28 2010-01-28 University Of Kansas Heat shock protein 90 inhibitor dosing methods
JP5766617B2 (ja) 2009-02-20 2015-08-19 ユニバーシティ・オブ・カンザス 修飾された糖部分を有するノボビオシン類似体
US20110082098A1 (en) 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
ES2647889T3 (es) 2011-04-05 2017-12-27 Sloan-Kettering Institute For Cancer Research Inhibidores de la Hsp90
US9056104B2 (en) 2011-05-20 2015-06-16 The University Of Kansas Dynamic inhibitors of heat shock protein 90
WO2013112548A1 (en) 2012-01-23 2013-08-01 University Of South Florida Gamma-aapeptides with potent and broad-spectrum antimicrobial activity
SMT201900660T1 (it) 2012-02-09 2020-01-14 Univ Kansas Inibitori c-terminali di hsp90
US9422230B2 (en) 2013-05-09 2016-08-23 Council Of Scientific And Industrial Research Process for the preparation of an anticonvulsant agent pregabalin hydrochloride
AU2014346483B2 (en) 2013-11-07 2019-01-17 The University Of Kansas Biphenylamide derivative Hsp90 inhibitors
CA2929243C (en) 2013-11-11 2022-05-03 The University Of Kansas Coumarin based hsp90 inhibitors with urea and ether substituents
CA2951270C (en) 2014-06-13 2023-07-04 The University Of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
MX388516B (es) * 2014-06-24 2025-03-20 Univ Kansas Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70.
JP7508375B2 (ja) 2018-05-14 2024-07-01 リアタ ファーマシューティカルズ インコーポレイテッド 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Similar Documents

Publication Publication Date Title
JP2021524439A5 (https=)
JP2017521496A5 (https=)
JP7704529B2 (ja) インテグリン標的化リガンドとその使用
JP2021521200A5 (https=)
JP2024001048A5 (https=)
EP3672591B1 (en) Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop
WO1998045249A1 (en) 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JP2018509404A5 (https=)
JP7808963B2 (ja) ＨＩＦ－２アルファ（ＥＰＡＳ１）の発現を阻害するためのＲＮＡｉ剤、その組成物及び使用方法
JP2017019854A (ja) 自己免疫性疾患の処置剤
JP2007529426A5 (https=)
US20140179919A1 (en) Compounds, compositions, methods of synthesis, and methods of treatment
JPWO2019222269A5 (https=)
JPWO2020092019A5 (https=)
JP2021533115A5 (https=)
AU2020103878A4 (en) Compounds and methods for treating influenza
JP7506660B2 (ja) デンドリマー製剤
JP2023002841A (ja) 高血圧症及び／又は線維症を処置するための組成物
MXPA02004355A (es) Composiciones de profarmacos de acido 6-metoxi-2-naftilacetico para tratar la inflamacion.
JP2018525346A5 (https=)
JPH0237357B2 (https=)
JPWO2022195454A5 (https=)
TH2001006527A (th) ไบเอริล เอไมด์ที่มีหมู่น้ำตาลที่ถูกดัดแปลงสำหรับการบำบัดโรคที่เกี่ยวข้องกับวิถีของฮีตช็อคโปรตีน
JPWO2020028222A5 (https=)
JPWO2022093552A5 (https=)